category,datetime,headline,id,image,related,source,summary,url
company,1768426200,TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide,138115521,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,JNJ,Yahoo,"Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® (teclistamab-cqyv) monotherapy, showing a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death in a patient population that was predominantly refractory to anti-CD38 therapy and lenalidomide. Data confirm superior progression-free survival (PFS) and overall survival (OS",https://finnhub.io/api/news?id=76a81f13707634522ba0ee5ce9fff6c2b4a3636147847a4a3e145ee02ca7764c
company,1768410360,Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?,138114642,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,JNJ,Yahoo,"BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.",https://finnhub.io/api/news?id=7ce1b1792f772789e4085bcc16c3acfd003ce3da153685f709c20b9d286d902b
company,1768402804,Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth,138113136,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,JNJ,Yahoo,Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=d92db0c3d3b190da2c4d174c2ffdd8872eee358e47f549acaeda9dde10afbc1e
company,1768399205,Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know,138113137,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,JNJ,Yahoo,"Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",https://finnhub.io/api/news?id=ce4b314e947f23696c29a46cc1175760cadeb7d705b52bdb17e58bfb236ba8c0
company,1768391739,Update: Market Chatter: Johnson & Johnson Convinces Court to Recalculate $1 Billion Auris Award,138111156,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,JNJ,Yahoo,(Updates with Johnson & Johnson's response in the fourth paragraph.) Johnson & Johnson (JNJ) co,https://finnhub.io/api/news?id=ee5e04a33ed009b7d96c8f70092af358630ab2a26c028d1fc3541abe15582a2d
